Ambroxol lozenge bioavailability - An open-label, two-way crossover study of the comparative bioavailability of ambroxol lozenges and commercial tablets in healthy Thai volunteers

被引:9
|
作者
Rojpibulstit, M [1 ]
Kasiwong, S [1 ]
Juthong, S [1 ]
Phadoongsombat, N [1 ]
Faroongsarng, D [1 ]
机构
[1] Prince Songkla Univ, Fac Pharmaceut Sci, Songkhla, Thailand
关键词
D O I
10.2165/00044011-200323040-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To compare the bioavailability of two 15mg ambroxol lozenges with a commercial 30mg ambroxol tablet. Design: Open-label, two-way crossover study. Method: Each formulation was randomly administered to 20 healthy Thai volunteers (ten male and ten female) with a 1-week washout period between formulations. After administration, serial blood samples were collected over a 24-hour period and the plasma concentration of ambroxol was subsequently measured using high performance liquid chromatography with ultraviolet detection after liquid-liquid extraction. Pharmacokinetic parameters were analysed by a noncompartmental pharmacokinetic model and compared between formulations using analysis of variance with a significance level of 0.05. Results: The point estimates (90% CI) of the area under the plasma concentration-time curve (AUC) and peak plasma concentration (C-max) ratios between lozenge and commercial tablet were 1.07 (0.89 to 1.28) and 1.20 (1.04 to 1.40), respectively. The point estimate (90% CI) of the difference between formulations for time to C-max was 0.40 (-0.20 to 1.00). Conclusion: The two formulations under test were not bioequivalent based on the stipulated bioequivalence criteria. The biclavailability from the ambroxol lozenge might be better, since the 90% CI of the AUC(0-infinity) fell outside the bioequivalence range, and its range was narrower. The difference in rate of absorption was not conclusive because ambroxol was delivered from the lozenge by two parallel processes, namely absorption via oral and gastrointestinal mucosa. The additional oral mucosal absorption might not only contribute more absorption but also introduce variability compared with that of tablet administration. The relative importance of oral versus gastrointestinal mucosal absorption of ambroxol from the lozenge formulation, and the clinical significance of this, requires further study.
引用
下载
收藏
页码:273 / 280
页数:8
相关论文
共 50 条
  • [11] Relative Bioavailability and Pharmacokinetic Properties of Two Different Enteric Formulations of Esomeprazole in Healthy Bangladeshi Male Volunteers: An Open-Label, Single-Dose, Randomized-Sequence, Two-Way Crossover Study
    Ullah, Md. Ashik
    Shams-Ud-Dowla
    Al Maruf, Abdullah
    Azad, Mohammad Abul Kalam
    Shohag, Md. Hasanuzzaman
    Sultana, Rebeka
    Latif, A. H. M. Mahbub
    Hasnat, Abul
    CLINICAL THERAPEUTICS, 2010, 32 (07) : 1419 - 1426
  • [13] Comparative Fasting Bioavailability of Dispersible and Conventional Tablets of Risperidone: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Male Chinese Volunteers
    Huang, Mingzhu
    Shen-Tu, Jianzhong
    Hu, Xingjiang
    Chen, Junchun
    Liu, Jian
    Wu, Lihua
    CLINICAL THERAPEUTICS, 2012, 34 (06) : 1432 - 1439
  • [14] Relative bioavailability of levodropropizine 60 mg capsule and syrup formulations in healthy male Korean volunteers: a single-dose, randomized-sequence, open-label, two-way crossover study
    Jang, Jae-Won
    Seo, Ji-Hyung
    Jo, Min-Ho
    Lee, Young-Joo
    Cho, Young-Wuk
    Yim, Sung-Vin
    Lee, Kyung-Tae
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (02) : 152 - 160
  • [15] Bioavailability of once-daily amantadine extended-release tablets in healthy adult volunteers: Results from a randomized, crossover, open-label study
    Kumar, Sudershan
    Srivastava, Abhishek
    Devkare, Prashant
    Bedi, Simrata
    Khuroo, Arshad
    Singh, Romi
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [16] Comparative Randomized, Single-Dose, Two-Way Crossover Open-Label Study to Determine the Bioequivalence of Two Formulations of Dalfampridine Tablets
    Al Bawab, Abdel Qader
    Alkhalidi, Bashar A.
    Albarahmieh, Esra'a
    Qassim, Sami M. A.
    Al-Saifi, Mohammad A. D.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (03): : 355 - 360
  • [17] Comparative Fasting Bioavailability of 2 Bepotastine Formulations in Healthy Male Chinese Volunteers: An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study
    Shentu, Jianzhong
    Zhou, Huili
    Hu, Xingjiang
    Wu, Guolan
    Wu, Lihua
    Zhu, Meixiang
    Zhai, You
    Zheng, Yunliang
    Liu, Jian
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 579 - 585
  • [18] Comparative bioavailability of two tablet formulations of emtricitabine/tenofovir in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study
    Keller, Guillermo A.
    Czerniuk, Paola
    Angel Bertuola, Roberto
    Mendez, Mariana
    Isabel Gimenez, Maria
    Di Girolamo, Guillermo
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (10) : 825 - 834
  • [19] The gastric modifier esomeprazole did not affect the bioavailability and tolerability of CS-7017 in an open-label, phase I, two-way crossover clinical study in healthy subjects
    Scheyer, R.
    Zahir, H.
    Luo, R.
    He, L.
    Noveck, R.
    Liu, K.
    EJC SUPPLEMENTS, 2010, 8 (07): : 101 - 101
  • [20] Bioequivalence study of two formulations of Enalapril, at a single oral dose of 20 mg (Tablets):: A randomized, two-way, open-label, crossover study in ealthy volunteers
    Protolés, A
    Terleira, A
    Almeida, S
    García-Arenillas, M
    Caturla, MC
    Filipe, A
    Vargas, E
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2004, 65 (01): : 34 - 46